TY - JOUR T1 - Current and upcoming anti-VEGF therapies and dosing strategies for the treatment of neovascular AMD: a comparative review JF - BMJ Open Ophthalmology JO - BMJ Open Ophth DO - 10.1136/bmjophth-2019-000398 VL - 4 IS - 1 SP - e000398 AU - Saira Khanna AU - Rahul Komati AU - David A Eichenbaum AU - Ishani Hariprasad AU - Thomas A Ciulla AU - Seenu M Hariprasad Y1 - 2019/12/01 UR - http://bmjophth.bmj.com/content/4/1/e000398.abstract N2 - Age-related macular degeneration is the leading cause of vision loss in the developed world, with the expected number of affected elderly individuals reaching 17.8 million. Antivascular endothelial growth factor (anti-VEGF) injection therapy has been instrumental in treating a disease process that was previously thought to be untreatable. Over the past two decades, landmark studies have demonstrated the efficacy of different anti-VEGF medications and investigated the optimal dosing regimen and delivery mechanism to increase overall vision and minimise patient burden. In this review, we outline landmark neovascular age-related macular degeneration clinical trials that have demonstrated level 1 evidence for its usage or have contributed to the understanding of how to dose these agents. ER -